Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy
- 1 December 2003
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 17 (18) , 2615-2622
- https://doi.org/10.1097/00002030-200312050-00008
Abstract
Objectives: To compare the survival and treatment responses to antiretroviral therapy between HIV-1-infected patients with active TB (TB patients) and without (non-TB patients) in the era of highly active antiretroviral therapy (HAART). Design: 8-year prospective observational study at a university hospital. Methods: A total of 125 (17.5%) TB patients (median CD4 cell count at TB diagnosis, 37 × 106 cells/l) and 591 non-TB patients (CD4 cell count at enrolment, 79 × 106 cells/l) were prospectively observed between June 1994 and October 2002. Virologic and immunologic responses were assessed in 230 antiretroviral-naive non-TB patients and 46 TB patients who concurrently initiated antituberculous therapy and HAART. The clinical outcome was evaluated by comparing incidence of new AIDS-associated opportunistic illnesses (OIs) and survival of all TB and non-TB patients. Results: Among antiretroviral-naive patients, CD4 cell count increase (71 versus 64 × 106 cells/l, P = 0.70) and proportions of patients achieving undetectable plasma viral load [20 of 46 versus 107 of 230, relative risk (RR), 0.93; 95% confidence interval (95% CI), 0.65–1.34; P = 0.71] at week 4 of HAART were similar between the 46 TB and 230 non-TB patients, as was the virologic failure during HAART (RR, 1.49; 95% CI, 0.92–2.41; P = 0.14). The risk for HIV progression to new OIs was also similar between the two groups (adjusted RR, 1.16; 95% CI, 0.764–1.77). The adjusted hazard ratio for death of TB patients compared with non-TB patients was 1.18 (95% CI, 0.65–2.32) before HAART era and 0.89 (95% CI, 0.57–1.69) in HAART era. Conclusions: Our data indicated that virologic, immunologic, and clinical responses to HAART and prognosis of HIV-1-infected TB patients who were concurrently treated with antituberculous therapy and HAART were similar to those of non-TB patients.Keywords
This publication has 28 references indexed in Scilit:
- Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan AfricaAIDS, 2001
- Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in UgandaAIDS, 2000
- Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South AfricaAIDS, 1999
- Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiologyAIDS, 1999
- Human Immunodeficiency Virus and the Outcome of Treatment for New and Recurrent Pulmonary Tuberculosis in African PatientsAmerican Journal of Respiratory and Critical Care Medicine, 1999
- High mortality rates among patients with tuberculosis in Bangui, Central African RepublicThe Lancet, 1997
- Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. The Makerere University-Case Western Reserve University Research Collaboration.American Journal of Respiratory and Critical Care Medicine, 1996
- Two-year follow-up of persons with HIV-1− and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West AfricaAIDS, 1995
- Cohort Study of Human Immunodeficiency Virus Infection in Patients with Tuberculosis in Nairobi, Kenya: Analysis of Early (6-Month) MortalityAmerican Review of Respiratory Disease, 1992
- Increased Mortality and Tuberculosis Treatment Failure Rate among Human Immunodeficiency Virus (HIV) Seropositive Compared with HIV Seronegative Patients with Pulmonary Tuberculosis Treated with “Standard” Chemotherapy in Kinshasa, ZaireAmerican Review of Respiratory Disease, 1991